Management of elderly patients with esophageal squamous cell cancer

Author:

Hamamoto Yasuo1ORCID,Murakami Kentaro2ORCID,Kato Ken3ORCID,Kitagawa Yuko4

Affiliation:

1. Keio Cancer Center , Keio University Hospital, School of Medicine, Tokyo, Japan

2. Department of Frontier Surgery , Graduate School of Medicine, Chiba University, Chiba, Japan

3. Department of Head and Neck , Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

4. Department of Surgery , Keio University School of Medicine, Tokyo, Japan

Abstract

AbstractThis review focuses on the treatment about elderly esophageal cancer to clarify the current situation regarding our clinical question. Although there are several reviews about elderly esophageal cancer treatment, there are fundamental differences between Japan and the rest of the world. Two main differences are raised: histological differences and treatment strategies for resectable patients. We overview each status according to following clinical questions. First, there are no established evaluation criteria for frail. Second, selection criteria for surgery or non-surgery are not established. Third, few specific treatments for elderly patients (EPs) are investigated. In conclusion, there are many reports about treatment of esophageal squamous cell carcinoma for EPs, although treatment strategy is still controversial. We have to consider well-designed prospective trial to confirm specific treatment strategy according to each stage.

Funder

Chugai Pharmaceutical Company, Ltd

Taiho Pharmaceutical Company, Ltd

Fujifilm, Toyama Chemical Company, Ltd

Abbott Japan Company, Ltd

KCI Licensing, Inc

Tsumura & Company, Ltd

Sanofi K.K., Eisai Company, Ltd

Japan Blood Products Organization Medtronic Japan Company, Ltd

Nihon Pharmaceutical Company, Ltd

Ono Pharmaceutical Company, Ltd

Pfizer Japan, Inc

Kyouwa Hakkou Kirin Company, Ltd

Taisho Toyama Pharmaceutical Company, Ltd

Dainippon Sumitomo Pharma Company, Ltd

Medicon, Inc

Astellas Pharma, Inc

Kowa Pharmaceutical Company, Ltd

Kaken Pharmaceutical Company, Ltd

Shionogi Company, Ltd

Otsuka Pharmaceutical Factory, Inc

Takeda Pharmaceutical Company, Ltd

Otsuka Pharmaceutical Company, Ltd

EA Pharma Company, Ltd

Asahi Kasei Company, Ltd

Merck Serono Company, Ltd

Daiichi Sankyo Company, Ltd

Yakult Honsha Company, Ltd

Nihon Pharmaceutical Co, Ltd

Ono Pharmaceutical Company

Taisho Toyama Pharmaceutical Company

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3